Apoptotic and cell cycle regulatory markers in uterine leiomyosarcoma

Gynecologic Oncology

Volumn 101, Issue 1, 2006, Pages 86-91

  Leiser, Aliza L ^a   Anderson, Sibyl E ^a   Nonaka, Daisuke ^a   Chuai, Shaokun ^a   Olshen, Adam B ^a   Chi, Dennis S ^a   Soslow, Robert A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Apoptosis; Bax; bcl 2; p21; p53; Tissue microarray; Uterine leiomyosarcoma

Indexed keywords

PROTEIN BAX; PROTEIN BCL 2; PROTEIN P21; PROTEIN P27; PROTEIN P53;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER DIAGNOSIS; CANCER SURVIVAL; CELL CYCLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEIOMYOMA; LEIOMYOSARCOMA; MAJOR CLINICAL STUDY; MOLECULAR DYNAMICS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; UTERUS MYOMA;

ADULT; AGED; APOPTOSIS; CELL CYCLE; CELL CYCLE PROTEINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LEIOMYOSARCOMA; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; UTERINE NEOPLASMS;

EID: 33644531583     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2005.09.055     Document Type: Article

References (38)

1. A. Berchuck, S.C. Rubin, W.J. Hoskins, P.E. Saigo, V.K. Pierce, and J.L. Lewis Jr. Treatment of uterine leiomyosarcoma Obstet. Gynecol. 71 6 Pt. 1 1988 845 850
2. N.B. Hornback, G. Omura, and F.J. Major Observations on the use of adjuvant radiation therapy in patients with stage I and II uterine sarcoma Int. J. Radiat. Oncol., Biol., Phys. 12 1986 2127 2130
3. D.G. Gallup, J.A. Blessing, W. Andersen, M.A. Morgan Gynecologic Oncology Group Study Evaluation of paclitaxel in previously treated leiomyosarcoma of the uterus: a gynecologic oncology group study Gynecol. Oncol. 89 2003 48 51
4. R.L. Giuntoli II, and R.E. Bristow Uterine leiomyosarcoma: present management Curr. Opin. Oncol. 16 2004 324 327
5. E.E. Sheets, and J. Yeh The role of apoptosis in gynaecological malignancies Ann. Med. 29 1997 121 126
6. S. de Vos, S.P. Wilczynski, M. Fleischhacker, and P. Koeffler p53 alterations in uterine leiomyosarcomas versus leiomyomas Gynecol. Oncol. 54 1994 205 208
7. H. Patterson, S. Gill, and C. Fisher Abnormalities of the p53 MDM2 and DCC genes in human leiomyosarcomas Br. J. Cancer 69 1994 1052 1058
8. S. Haupt, M. Berger, Z. Goldberg, and Y. Haupt Apoptosis-The p53 network J. Cell Sci. 116 Pt 20 2003 4077 4085
9. K. Kokawa, T. Shikone, T. Otani, and R. Nakano Apoptosis and the expression of Bax and Bcl-2 in squamous cell carcinoma and adenocarcinoma of the uterine cervix Cancer 85 1999 1799 1809
10. A. Linjawi, M. Kontogiannea, F. Halwani, M. Edwardes, and S. Meterissian Prognostic significance of p53, bcl-2, and Bax expression in early breast cancer J. Am. Coll. Surg. 198 2004 83 90
11. H.A. Saleh, H. Jackson, G. Khatib, and M. Banerjee Correlation of bcl-2 oncoprotein immunohistochemical expression with proliferation index and histopathologic parameters in colorectal neoplasia Pathol. Oncol. Res. 5 1999 273 279
12. K. Polyak, M.H. Lee, and H. Erdjument-Bromage Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals Cell 78 1994 59 66
13. E.S. Bales, C. Dietrich, and D. Bandyopadhyay High levels of expression of p27KIP1 and cyclin E in invasive primary malignant melanomas J. Invest. Dermatol. 113 1999 1039 1046
14. C. Catzavelos, N. Bhattacharya, and Y.C. Ung Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer Nat. Med. 3 1997 227 230
15. C. Catzavelos, M.S. Tsao, G. DeBoer, N. Bhattacharya, F.A. Shepherd, and J.M. Slingerland Reduced expression of the cell cycle inhibitor p27Kip1 in non-small cell lung carcinoma: a prognostic factor independent of Ras Cancer Res. 59 1999 684 688
16. W. Yang, K.S. Klos, and X. Zhou ErbB2 overexpression in human breast carcinoma is correlated with p21Cip1 up-regulation and tyrosine-15 hyperphosphorylation of p34Cdc2: poor responsiveness to chemotherapy with cyclophoshamide methotrexate, and 5-fluorouracil is associated with Erb2 overexpression and with p21Cip1 overexpression Cancer 98 2003 1123 1130
17. W. Remmele, and K.H. Schicketanz Immunohistochemical determination of estrogen and progesterone receptor content in human breast cancer. Computer-assisted image analysis (QIC score) vs. subjective grading (IRS) Pathol. Res. Pract. 189 8 1993 Sep. 862 866
18. T. Uchida, J.P. Gao, and C. Wang Antitumor effect of bcl-2 antisense phosphorothioate oligodeoxynucleotides on human renal-cell carcinoma cells in vitro and in mice Mol. Urol. 5 2001 71 78
19. K.S. Shin, B.A. Sullenger, and S.W. Lee Ribozyme-mediated induction of apoptosis in human cancer cells by targeted repair of mutant p53 RNA Mol. Ther. 10 2004 365 372
20. S.W. Bell, R.L. Kempson, and M.R. Hendrickson Problematic uterine smooth muscle neoplasms. A clinicopathologic study of 213 cases Am. J. Surg. Pathol. 18 1994 535 558
21. A. Gaumann, D.S. Tews, and T. Mentzel Expression of drug resistance related proteins in sarcomas of the pulmonary artery and poorly differentiated leiomyosarcomas of other origin Virchows. Arch. 442 2003 529 537 [electronic publication 2003 May 13]
22. H. Toyoshima, and T. Hunter p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21 Cell 78 1994 67 74
23. W.S. el-Deiry, T. Tokino, and V.E. Velculescu WAF1, a potential mediator of p53 tumor suppression Cell 75 1993 817 825
24. B. Eymin, M. Haugg, N. Droin, O. Sordet, M.T. Dimanche-Boitrel, and E. Solary p27Kip1 induces drug resistance by preventing apoptosis upstream of cytochrome c release and procaspase-3 activation in leukemic cells Oncogene 18 1999 1411 1418
25. B.G. Wouters, A.J. Giaccia, N.C. Denko, and J.M. Brown Loss of p21Waf1/Cip1 sensitizes tumors to radiation by an apoptosis-independent mechanism Cancer Res. 57 1997 4703 4706
26. S. Liu, W.R. Bishop, and M. Liu Differential effects of cell cycle regulatory protein p21(WAF1/Cip1) on apoptosis and sensitivity to cancer chemotherapy Drug Resist. Updat. 6 2003 183 195
27. J.P. Palazzo, W.E. Mercer, A.J. Kovatich, and M. McHugh Immunohistochemical localization of p21(WAF1/CIP1) in normal, hyperplastic, and neoplastic uterine tissues Hum. Pathol. 28 1997 60 66
28. Y. Dobashi, T. Noguchi, S. Nasuno, K. Katayama, and T. Kameya CDK-inhibitors-associated kinase activity: a possible determinant of malignant potential in smooth muscle tumors of the external soft tissue Int. J. Cancer 94 2001 353 362
29. K.M. Martel, A.C. Ko, G.M. Christman, and J.M. Stribley Apoptosis in human uterine leiomyomas Semin. Reprod. Med. 22 2004 91 103
30. H. Matsuo, T. Maruo, and T. Samoto Increased expression of Bcl-2 protein in human uterine leiomyoma and its up-regulation by progesterone J. Clin. Endocrinol. Metab. 82 1997 293 299
31. A.B. Schiller, W.S. Clark, G. Cotsonis, D. Lawson, P.B. DeRose, and C. Cohen Image cytometric bcl-2:bax and bcl-2:bcl-x ratios in invasive breast carcinoma: correlation with prognosis Cytometry 50 2002 203 209
32. I.R. Bukholm, G. Bukholm, and J.M. Nesland Reduced expression of both Bax and Bcl-2 is independently associated with lymph node metastasis in human breast carcinomas APMIS 110 2002 214 220
33. A. Jansson, and X.F. Sun Bax expression decreases significantly from primary tumor to metastasis in colorectal cancer J. Clin. Oncol. 20 2002 811 816
34. T. Ito, S. Fujieda, and H. Tsuzuki Decreased expression of Bax is correlated with poor prognosis in oral and oropharyngeal carcinoma Cancer Lett. 140 1999 81 91
35. K. Bodner, B. Bodner-Adler, O. Kimberger, K. Czerwenka, and K. Mayerhofer Bcl-2 receptor expression in patients with uterine smooth muscle tumors: an immunohistochemical analysis comparing leiomyoma, uterine smooth muscle tumor of uncertain malignant potential, and leiomyosarcoma J. Soc. Gynecol. Investig. 11 2004 187 191
36. Y.L. Zhai, T. Nikaido, T. Toki, A. Shiozawa, A. Orii, and S. Fujii Prognostic significance of bcl-2 expression in leiomyosarcoma of the uterus Br. J. Cancer 80 1999 1658 1664
37. T. Hong, Y. Shimada, and S. Uchida Expression of angiogenic factors and apoptotic factors in leiomyosarcoma and leiomyoma Int. J. Mol. Med. 8 2001 141 148
38. K. Schelwies, I. Sturm, and P. Grabowski Analysis of p53/BAX in primary colorectal carcinoma: low BAX protein expression is a negative prognostic factor in UICC stage III tumors Int. J. Cancer 99 2002 589 596